PoreWise Skin concern
Psoriasis
Primary sourcePsoriasis: a chronic immune-mediated condition that speeds up skin-cell turnover, producing raised, red, scaly plaques. The strongest evidence comes from a 2017 human trial: In 24 people with mild-to-moderate plaque psoriasis, a vitamin B12-containing ointment reduced PASI by 87.6% from baseline at week 12 versus 23.1% with a standard glycerol-petrolatum emollient on the opposite side (p < 0.001).
The two studies tested emollient or vitamin-B12 / zinc-pyrithione moisturizer care in diagnosed patients as supportive therapy. This is adjunct care alongside a clinician's plan.
Where the definition comes from
Source wording
“Approximately 125 million people worldwide have psoriasis … Plaque psoriasis is the most common variant of psoriasis.” — Armstrong et al., JAMA 2020 (PMID 32427307).
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA (Armstrong AW)
Ingredients at a glance
2017 · 24 people · patients with plaque psoriasis · PMID 29048238
| Ingredient | Measured outcome | Based on | Certainty | Year |
|---|---|---|---|---|
| — | Skin effect | Human trial | Low | 2017 |
| — | Skin effect | Human trial | Low | 2011 |
Study limits
Study conditions and measured outcomes.
-
ev-psoriasis-vitamin-b12-emollient Human trial · 2017
Single centre, 24 participants, single-blind, localised left-right design in the maintenance phase; the mainstream high-quality evidence for psoriasis still comes from prescription drugs and biologics.
-
ev-psoriasis-zinc-pyrithione-rct Human trial · 2011
Limited to localised, mild psoriasis; an over-the-counter active ingredient.
Research-backed approaches
These studies measured finished products and whole routines.
- 1 Skin effectSuperiority of a vitamin B(12)-containing emollient compared to a standard emollient in the maintenance treatment of mild-to-moderate plaque psoriasis
In 24 people with mild-to-moderate plaque psoriasis, a vitamin B12-containing ointment reduced PASI by 87.6% from baseline at week 12 versus 23.1% with a standard glycerol-petrolatum emollient on the opposite side (p < 0.001).
Human trial · 2017 · 24 people · patients with plaque psoriasis · Adults with plaque psoriasis in the maintenance phase, applying the ointment twice daily for 12 weeks in a randomised, single-blind, left-right paired design. · Single centre, 24 participants, single-blind, localised left-right design in the maintenance phase; the mainstream high-quality evidence for psoriasis still comes from prescription drugs and biologics.
- 2 Skin effectTreatment of localized psoriasis with a topical formulation of zinc pyrithione
In a randomized, double-blind trial of 60 people with localised psoriasis, a 0.25% zinc pyrithione cream reduced mean PASI from 3.4 to 0.9 over 3 months (p < 0.01) and was significantly better than the emollient base, which changed from 4.3 to 3.9 (p > 0.05).
Human trial · 2011 · 60 people · patients with localised psoriasis (30/30) · People with localised psoriasis affecting less than 10% of body surface area, applying the cream twice daily for 3 months. · Limited to localised, mild psoriasis; an over-the-counter active ingredient.
Common questions
- How many people were studied?
- 2 findings · 2017 · 24 people · patients with plaque psoriasis · PMID 29048238
- What can I use for Psoriasis?
- 2017 · 24 people · patients with plaque psoriasis · PMID 29048238
- Can I use these every day for Psoriasis?
- Adults with plaque psoriasis in the maintenance phase, applying the ointment twice daily for 12 weeks in a randomised, single-blind, left-right paired design（2017 · 24 participants · 24 patients with plaque psoriasis · PMID 29048238） People with localised psoriasis affecting less than 10% of body surface area, applying the cream twice daily for 3 months（2011 · 60 participants · 60 patients with localised psoriasis (30/30) · PMID 22367374）